A Better Newspaper

## Pattern: Structural Tilt Toward IP Rights Holders Across Multiple Venues and Doctrines Three distinct legal developments in 2026 — the PTAB IPR institution rate collapse, the UPC PI jurisprudence cementing in medical devices, and the DOJ's SEP/RAND antitrust position — are not isolated. Together they represent a coordinated structural shift in the global IP enforcement landscape that systematically advantages patent holders over implementers. ### The three vectors **Vector 1 – PTAB IPR collapse:** Institution rates falling from ~65% to ~37% means accused infringers have lost their most reliable US invalidity vehicle. Companies that built patent defense strategies around IPR petitions must now rebuild around district court litigation, appeals, or licensing — all more expensive and slower. **Vector 2 – UPC PI enforcement:** The UPC Court of Appeal upholding a PI against a Chinese manufacturer (Sinocare) and its European distributor signals that the UPC is a patent holder's venue — willing to impose pan-European injunctions rapidly, including against foreign manufacturers with indirect European presence. The Hague local division is cementing as the PI venue of choice. **Vector 3 – DOJ SEP/RAND antitrust narrowing:** The DOJ's position that SEP status does not create antitrust market power presumption removes a key defensive tool for standard implementers in licensing negotiations. RAND commitments are now primarily a contract law issue, not an antitrust weapon. ### Why these are a unified pattern Each development independently advantages patent holders. Together, they close off three of the primary defensive pathways available to accused infringers or unwilling licensees: US administrative invalidity (PTAB), European injunctive relief defense (UPC), and antitrust counterclaims (DOJ/SEP). The cumulative effect is a global IP enforcement environment materially more favorable to patent holders than at any point in the past decade. ### Strategic implications - **Licensing:** RAND and SEP holders should accelerate licensing campaigns; leverage has shifted decisively in their favor. - **M&A due diligence:** Patent exposure is more serious in 2026 than historical base rates suggest; IPR fallback assumptions must be revised downward. - **Portfolio strategy:** Defensive patent portfolios need revaluation upward; offensive portfolio monetization windows are more favorable. - **Product design:** Standard-essential technology choices carry higher lock-in risk as RAND antitrust defenses weaken. - **European market entry:** Foreign manufacturers (especially Chinese) must now treat UPC PI risk as a real market-access barrier, not a remote litigation risk.